NCT06705608 - Examining the Risk of Skin Cancer in Multiple Sclerosis Patients Using Fingolimod: a Population-Based Study | Biotech Hunter

Enrollment

4,000

Participants

Timeline

Start Date

January 1, 2003

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions

Multiple SclerosisSkin CancerSkin Cancer MelanomaSkin Cancers - Basal Cell CarcinomaSkin Cancer, Squamous CellMultiple Sclerosis (MS) - Relapsing-remitting

Interventions

DRUG

Fingolimod

patients who received fingolimod for treating RRMS

DRUG

Natalizumab

patients who received natalizumab for treating RRMS (active comparator)

DRUG

Dimethyl fumarate (DMF)

patients who received dimethyl fumarate for treating RRMS (active comparator)

DRUG

Alemtuzumab

patients who received alemtuzumab for treating RRMS (active comparator)

DRUG

Teriflunomide

patients who received teriflunomide for treating RRMS (active comparator)

All Listed Sponsors

lead

University of British Columbia

OTHER